Regatta Bio received an undisclosed investment to advance its portfolio of regulatory T cell (Treg) therapies designed to treat immune-mediated and rare disorders, including chronic graft-versus-host disease (cGvHD), solid organ rejection, autoimmune diseases, and inflammatory conditions.
